Dennis Wright - REALORD GRP Insider

REALORD GRP HLDGS HD 10 -- Germany Stock  

EUR 0.51  0.04  8.51%

Acting Chief Scientific Officer

Dr. Dennis J. Wright, BPharm, MSc, Ph.D., is Acting Chief Scientific Officer of Clinuvel Pharmaceuticals Ltd since September 2012. He was previously Vice President Scientific Affairs of the Company. Dr. Wright has a range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager. Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen . He has a Pharmacy degree and postgraduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne
  Executive Since 2012      
Wright is responsible for the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Management Efficiency

Entity Summary

REALORD GRP HLDGS HD 10 (CUV) is traded on Berlin Stock Exchange in Germany. and employs 8 people.

Did you try this?

Run Performance Analysis Now
   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
Hide  View All  Next  Launch Performance Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add REALORD GRP HLDGS HD 10 to your portfolio

Top Management

REALORD GRP HLDGS Leadership Team
Willem Blijdorp, Director
Elie Ishag, Director
Stanley McLiesh, Chairman
Philippe Wolgen, CEO, MBA
Darren Keamy, CFO, CPA
Dennis Wright, Executive
Brenda Shanahan, Director

Stock Performance

REALORD GRP Performance Indicators